Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients

Paola Bertazzoni; Cristina Rabascio; Federica Gigli; Liliana Calabrese; Davide Radice; Angelica Calleri; Giuliana Gregato; Mara Negri; Sarah J. Liptrott; Simona Bassi; Luca Nassi; Simona Sammassimo; Daniele Laszlo; Lorenzo Preda; Giancarlo Pruneri; Laura Orlando; Giovanni Martinelli

doi:10.3109/10428194.2010.495799

Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients

Paola Bertazzoni, Cristina Rabascio, Federica Gigli, Liliana Calabrese, Davide Radice, Angelica Calleri, Giuliana Gregato, Mara Negri, Sarah J. Liptrott, Simona Bassi, Luca Nassi, Simona Sammassimo, Daniele Laszlo, Lorenzo Preda, Giancarlo Pruneri, Laura Orlando, Giovanni Martinelli

Istituto Europeo di Oncologia

Research output: Contribution to journal › Article › peer-review

Abstract

The aim of this study was to investigate the efficacy of combined treatment with rituximab and subcutaneous cladribine in patients with newly diagnosed and relapsed chronic lymphocytic leukemia (CLL). Forty-three patients with active CLL or small lymphocytic lymphoma received rituximab 375 mg/m ² on day 1 and cladribine 0.1 mg/kg subcutaneously on days 26. The treatment was repeated every 4 weeks for a total of four cycles. Sixteen patients were pretreated. The overall response rate was 88 (50 complete remission and 38 partial remission). The median time to treatment failure was 37.9 months. Grade 4 neutropenia developed in 5 of patients. The data indicate that combination therapy with rituximab and cladribine is a valuable and safe treatment for patients with CLL.

Original language	English
Pages (from-to)	1485-1493
Number of pages	9
Journal	Leukemia and Lymphoma
Volume	51
Issue number	8
DOIs	https://doi.org/10.3109/10428194.2010.495799
Publication status	Published - Aug 2010

Keywords

Chronic lymphocytic leukemia
rituximab
small lymphocytic lymphoma
subcutaneous cladribine

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.3109/10428194.2010.495799

Fingerprint Dive into the research topics of 'Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients'. Together they form a unique fingerprint.

Cite this

Bertazzoni, P., Rabascio, C., Gigli, F., Calabrese, L., Radice, D., Calleri, A., Gregato, G., Negri, M., Liptrott, S. J., Bassi, S., Nassi, L., Sammassimo, S., Laszlo, D., Preda, L., Pruneri, G., Orlando, L., & Martinelli, G. (2010). Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients. Leukemia and Lymphoma, 51(8), 1485-1493. https://doi.org/10.3109/10428194.2010.495799

Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients. / Bertazzoni, Paola; Rabascio, Cristina ; Gigli, Federica ; Calabrese, Liliana ; Radice, Davide ; Calleri, Angelica ; Gregato, Giuliana ; Negri, Mara ; Liptrott, Sarah J.; Bassi, Simona; Nassi, Luca; Sammassimo, Simona ; Laszlo, Daniele ; Preda, Lorenzo ; Pruneri, Giancarlo; Orlando, Laura; Martinelli, Giovanni.

In: Leukemia and Lymphoma, Vol. 51, No. 8, 08.2010, p. 1485-1493.

Research output: Contribution to journal › Article › peer-review

Bertazzoni, P, Rabascio, C , Gigli, F , Calabrese, L , Radice, D , Calleri, A , Gregato, G , Negri, M , Liptrott, SJ, Bassi, S, Nassi, L, Sammassimo, S , Laszlo, D , Preda, L , Pruneri, G, Orlando, L & Martinelli, G 2010, 'Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients', Leukemia and Lymphoma, vol. 51, no. 8, pp. 1485-1493. https://doi.org/10.3109/10428194.2010.495799

Bertazzoni, Paola ; Rabascio, Cristina ; Gigli, Federica ; Calabrese, Liliana ; Radice, Davide ; Calleri, Angelica ; Gregato, Giuliana ; Negri, Mara ; Liptrott, Sarah J. ; Bassi, Simona ; Nassi, Luca ; Sammassimo, Simona ; Laszlo, Daniele ; Preda, Lorenzo ; Pruneri, Giancarlo ; Orlando, Laura ; Martinelli, Giovanni. / Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients. In: Leukemia and Lymphoma. 2010 ; Vol. 51, No. 8. pp. 1485-1493.

@article{5603bc2c30454c3da71b4e48c7dc623d,

title = "Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients",

abstract = "The aim of this study was to investigate the efficacy of combined treatment with rituximab and subcutaneous cladribine in patients with newly diagnosed and relapsed chronic lymphocytic leukemia (CLL). Forty-three patients with active CLL or small lymphocytic lymphoma received rituximab 375 mg/m 2 on day 1 and cladribine 0.1 mg/kg subcutaneously on days 26. The treatment was repeated every 4 weeks for a total of four cycles. Sixteen patients were pretreated. The overall response rate was 88 (50 complete remission and 38 partial remission). The median time to treatment failure was 37.9 months. Grade 4 neutropenia developed in 5 of patients. The data indicate that combination therapy with rituximab and cladribine is a valuable and safe treatment for patients with CLL.",

keywords = "Chronic lymphocytic leukemia, rituximab, small lymphocytic lymphoma, subcutaneous cladribine",

author = "Paola Bertazzoni and Cristina Rabascio and Federica Gigli and Liliana Calabrese and Davide Radice and Angelica Calleri and Giuliana Gregato and Mara Negri and Liptrott, {Sarah J.} and Simona Bassi and Luca Nassi and Simona Sammassimo and Daniele Laszlo and Lorenzo Preda and Giancarlo Pruneri and Laura Orlando and Giovanni Martinelli",

year = "2010",

month = aug,

doi = "10.3109/10428194.2010.495799",

language = "English",

volume = "51",

pages = "1485--1493",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Taylor and Francis Ltd.",

number = "8",

}

TY - JOUR

T1 - Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients

AU - Bertazzoni, Paola

AU - Rabascio, Cristina

AU - Gigli, Federica

AU - Calabrese, Liliana

AU - Radice, Davide

AU - Calleri, Angelica

AU - Gregato, Giuliana

AU - Negri, Mara

AU - Liptrott, Sarah J.

AU - Bassi, Simona

AU - Nassi, Luca

AU - Sammassimo, Simona

AU - Laszlo, Daniele

AU - Preda, Lorenzo

AU - Pruneri, Giancarlo

AU - Orlando, Laura

AU - Martinelli, Giovanni

PY - 2010/8

Y1 - 2010/8

N2 - The aim of this study was to investigate the efficacy of combined treatment with rituximab and subcutaneous cladribine in patients with newly diagnosed and relapsed chronic lymphocytic leukemia (CLL). Forty-three patients with active CLL or small lymphocytic lymphoma received rituximab 375 mg/m 2 on day 1 and cladribine 0.1 mg/kg subcutaneously on days 26. The treatment was repeated every 4 weeks for a total of four cycles. Sixteen patients were pretreated. The overall response rate was 88 (50 complete remission and 38 partial remission). The median time to treatment failure was 37.9 months. Grade 4 neutropenia developed in 5 of patients. The data indicate that combination therapy with rituximab and cladribine is a valuable and safe treatment for patients with CLL.

AB - The aim of this study was to investigate the efficacy of combined treatment with rituximab and subcutaneous cladribine in patients with newly diagnosed and relapsed chronic lymphocytic leukemia (CLL). Forty-three patients with active CLL or small lymphocytic lymphoma received rituximab 375 mg/m 2 on day 1 and cladribine 0.1 mg/kg subcutaneously on days 26. The treatment was repeated every 4 weeks for a total of four cycles. Sixteen patients were pretreated. The overall response rate was 88 (50 complete remission and 38 partial remission). The median time to treatment failure was 37.9 months. Grade 4 neutropenia developed in 5 of patients. The data indicate that combination therapy with rituximab and cladribine is a valuable and safe treatment for patients with CLL.

KW - Chronic lymphocytic leukemia

KW - rituximab

KW - small lymphocytic lymphoma

KW - subcutaneous cladribine

UR - http://www.scopus.com/inward/record.url?scp=77955449996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955449996&partnerID=8YFLogxK

U2 - 10.3109/10428194.2010.495799

DO - 10.3109/10428194.2010.495799

M3 - Article

C2 - 20578816

AN - SCOPUS:77955449996

VL - 51

SP - 1485

EP - 1493

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 8

ER -